3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
33
Lung Neoplasms
13
Breast Neoplasms
12
Ovarian Neoplasms
11
Colorectal Neoplasms
11
Recurrence
9
Neoplasms
9
Small Cell Lung Carcinoma
8
Neoplasm Metastasis
8
Head and Neck Neoplasms
8
Urinary Bladder Neoplasms
7
Squamous Cell Carcinoma of Head and Neck
7
Lymphoma, Large B-Cell, Diffuse
7
Prostatic Neoplasms
6
Carcinoma, Hepatocellular
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
5
Diabetes Mellitus, Insulin-Dependent, 12
5
Carcinoma
5
Multiple Myeloma
4
Lymphoma, Follicular
4
Cholangiocarcinoma
4
Uterine Cervical Neoplasms
3
Recurrent Squamous Cell Lung Carcinoma
3
Oropharyngeal Neoplasms
3
Mouth Neoplasms
3
Mesothelioma
3
Lymphoma, Non-Hodgkin
3
Lymphoma
3
Kidney Neoplasms
3
Interventions
tremelimumab
1
durvalumab
1
Pemetrexed
1
Gemcitabine
1
Cisplatin
1
Carboplatin
1
Albumin-Bound Paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Non Small Cell Lung Cancer NSCLC
×
durvalumab
×
Clear all
NCT03164616
2026-03-13
POSEIDON
AstraZeneca
Phase 3
Active not recruiting
1,186 enrolled
26 charts
1 FDA